Led · Equity · Apr 2026

Floreo develops virtual-reality-based therapeutic experiences designed to help people with autism build social and communication skills within controlled immersive environments. The company is advancing its platform through an FDA review process and is using recent capital to continue product development while awaiting regulatory clearance. It received a $1 million investment from Cleveland Clinic Ventures, which the company says will support further technology development. Floreo plans to initiate a Series B financing round to secure additional funds for growth and expansion. The article does not report revenue, user counts, or other operating metrics. No founding year or location was provided in the article.

Participated · Series B · Jan 2026

Founded in 2010 and headquartered in Cleveland, Ohio, Enspire DBS Therapy is building a first-in-class neuromodulation solution that pairs deep brain stimulation (DBS) with structured rehabilitation to restore upper-extremity function after stroke. Its lead program is being evaluated in the multicenter RESTORE pivotal clinical trial, which implants a commercially available third-party DBS system and compares DBS + Rehab to rehabilitation alone in patients with chronic arm impairment. The study is being conducted under an FDA Investigational Device Exemption and is targeting long-term safety and effectiveness data needed for future U.S. marketing authorization, with interim results expected in mid-2027. Proceeds from recent funding will accelerate patient enrollment and trial execution. Financially, the company remains pre-commercial and recently secured $10.3 million in fresh capital, bringing additional institutional support and board expertise. Existing backers Cleveland Clinic and JobsOhio Ventures have recommitted to the venture alongside new lead investor Genesys Capital. Enspire aims to translate breakthrough neuroscience into clinically meaningful outcomes for the roughly 800,000 Americans who suffer a stroke each year.

Led · Series A · Oct 2025

MediView XR is a Cleveland-based med-tech company commercializing an augmented-reality ecosystem that fuses pre-operative CT data with live ultrasound to give clinicians ‘X-ray vision’ during interventions. Its FDA-cleared XR90 platform projects a 3D model of a patient’s internal anatomy directly onto the body, enabling head-up, hands-free guidance for biopsies, tumor ablations, injections, and other image-guided procedures. The system reduces physicians’ cognitive load by eliminating the need to translate 2D images into 3D mental maps and supports remote collaboration among care teams. MediView’s technology originated from Cleveland Clinic intellectual property and is positioned to become a new standard for less invasive care. With fresh capital, the company plans to accelerate commercial roll-out, expand industry partnerships, pursue additional regulatory approvals, and deepen AI-driven product development. Operational capacity will be scaled to meet increasing global demand. No revenue or user metrics were disclosed in the article.

Participated · Series A · Aug 2025

Method AI, led by CEO Doug Teany, is a Boston, MA-based medical technology company focused on improving oncology outcomes through image-guided surgical navigation. The company is developing a novel surgical ultrasound platform that visualizes anatomy deep below the visible surface of an organ and creates a 3D subsurface map for physicians. Its platform provides real-time guidance against an AI-generated surgical plan to assist procedures. Method AI aims to improve cancer-free survival rates for patients and has a stated potential to reduce over $1 billion in annual healthcare costs. The company raised $20M in Series A funding to support continued development of this surgical ultrasound platform.

Participated · Series A · Dec 2024

1m has developed a SaaS-based platform purpose-built to help healthcare systems manage financial, operational, and regulatory risk by integrating data, analytics and monitoring tools into existing risk management workflows. The platform delivers timely, high-ROI decision support and anomaly detection, with end-to-end risk assessment workflow tools that reduce administrative burdens. It provides continuously updated, healthcare-specific risk datasets to flag emerging threats and quantifies operating and balance sheet risks for integration with long-term financial and strategic planning. Leadership-friendly dashboards surface risk management program outputs to drive engagement, and the product includes built-in risk mitigation support via proprietary data monitoring and anomaly detection tools. The company is led by former Goldman Sachs healthcare investment bankers Jeff Ellis and Chris Giuliano. 1m plans to use the new funding to expand go-to-market efforts, enhance its intellectual property, and hire technical talent.